Enkephalin: A Literature Course on What the Published Studies Report

This course walks through the published literature on enkephalin in six modules. Each module states what the studies measured, what the authors reported, and then where the evidence stops. No module offers guidance on use, and nothing here describes a protocol. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health-related decision.

One framing point matters before Module 1. Most compounds discussed in peptide literature are synthetic analogues developed as candidate drugs. Enkephalin is different: it is a peptide the body already makes, and the bulk of the literature treats it as an endogenous signalling molecule to be measured rather than an agent to be administered. That shapes every module that follows.

Module 1 — What Enkephalin Is and How It Has Been Studied

Definition and class

Enkephalins are endogenous opioid pentapeptides — five-amino-acid chains produced within the nervous system and peripheral tissues. Two forms dominate the literature: Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu). Both are cleaved from a larger precursor protein, proenkephalin, and reviews of addiction neurobiology describe enkephalin within the broader family of endogenous opioid peptides that signal through opioid receptors in the brain (PMID 29892236), alongside related work describing enkephalinergic systems as a distinct arm of that family (PMID 35993087).

Origin and forms in the literature

Because the precursor is proenkephalin, some studies do not measure a single peptide at all but rather a set of proenkephalin-derived peptides; a 2018 rodent study used that framing when it examined these peptides in relation to mitochondrial respiratory control during epileptogenesis (PMID 30319356). Met-enkephalin also appears in a second literature under the name opioid growth factor, a label used in a rat study of transplacental transfer of [Met⁵]-enkephalin (PMID 11489341). Readers comparing papers should note that "met-enkephalin," "[Met5]-enkephalin" and "opioid growth factor" can refer to the same pentapeptide depending on the research tradition of the authors.

How it has been studied

• Tissue immunoreactivity. Researchers stained brain or liver tissue and quantified enkephalin signal — for example hippocampal mossy fibre Leu-enkephalin immunoreactivity in female rats (PMID 24275289) and hepatic met-enkephalin with delta opioid receptor-1 in human liver samples (PMID 18753988).
• Circulating levels in patients. An observational study measured plasma met-enkephalin, beta-endorphin and Leu-enkephalin in human hepatic encephalopathy (PMID 17684846).
• Transgenic and disease models. A mouse model of Alzheimer's disease was used to link enkephalin levels to neuronal and behavioural endpoints (PMID 18463254).
• Administration in animals. A mouse study delivered Leu-enkephalin intrathecally together with spinorphin, an endogenous inhibitor of enkephalin-degrading enzymes, and measured nociceptive endpoints (PMID 11829145).
• Cell culture. Met-enkephalin was applied to cytokine-stimulated murine macrophages and interleukin-6 output was measured (PMID 11021979).

Limits of the evidence in Module 1

Definitions and nomenclature vary between fields, and immunoreactivity is a proxy for peptide content rather than a direct concentration. None of the verified studies here established a standard reference range for enkephalin in healthy humans, and none compared measurement methods head to head.

Module 2 — Mechanism as Described in the Literature

Receptor-level description

The reviews in this set place enkephalin within opioid receptor signalling, with a particular emphasis on delta-opioid receptors; human liver work looked at met-enkephalin immunoreactivity together with delta opioid receptor-1 immunoreactivity in the same samples, consistent with a locally co-expressed ligand–receptor pair (PMID 18753988).

Circuit-level description in addiction research

A 2018 review described enkephalin as a pivotal player in neuroadaptations related to psychostimulant addiction, framing changes in enkephalin signalling as part of how reward circuitry adapts to repeated drug exposure (PMID 29892236). A 2022 review extended the same theme, examining the role of enkephalinergic systems across substance use disorders rather than a single drug class (PMID 35993087). Both are narrative syntheses, not experiments.

Degradation as part of the mechanism

Enkephalin signalling is limited by enzymes that break the pentapeptide down. Researchers exploited this directly: spinorphin, described as an endogenous inhibitor of enkephalin-degrading enzymes, potentiated Leu-enkephalin-induced anti-allodynic and antinociceptive effects in mice (PMID 11829145). In mechanistic terms, that result treats enzymatic breakdown as a controlling variable on enkephalin action.

Non-receptor and downstream observations

Two studies point beyond classical receptor pharmacology. Proenkephalin-derived peptides were reported to be involved in the modulation of mitochondrial respiratory control during epileptogenesis in a rodent model (PMID 30319356), and met-enkephalin was reported to augment interleukin-6 production by cytokine-stimulated murine macrophages (PMID 11021979), an immune-signalling endpoint rather than a neurological one.

Limits of the evidence in Module 2

Mechanistic claims here come from reviews, cell cultures and animal models. No study in this set demonstrated a receptor-level mechanism in living humans, and no study resolved how the mitochondrial and immune observations relate to opioid receptor engagement.

Module 3 — Reported Outcomes by Study

The table summarises what each paper modelled, what it measured and what the authors reported. Nothing in it should be read as a benefit claim; several entries describe findings that the authors interpreted as harmful.

Reading the direction of effect

Two entries deserve emphasis because they run in opposite directions. In the mouse pain model, higher effective Leu-enkephalin activity accompanied reduced pain-related responses (PMID 11829145). In the Alzheimer's model, the study reported that elevated enkephalin contributed to impairment rather than protection (PMID 18463254). More enkephalin signalling was therefore not uniformly favourable across the literature; context and tissue mattered.

Limits of the evidence in Module 3

These are heterogeneous designs with different species, routes and endpoints, and they cannot be pooled. The human studies were observational and measured associations, not causes. No randomised controlled trial of administered enkephalin appears in this verified set, so no clinical outcome can be attributed to the peptide.

Module 4 — Enkephalin Side Effects: What Studies Report

There is no clinical safety database for administered enkephalin in this literature, so "side effects" in the conventional sense — tabulated adverse events from dosed human volunteers — were not reported by any paper cited here. What the literature does contain are findings the authors themselves described as harmful, unwanted or disease-associated.

Findings interpreted as harmful

• Neuronal and behavioural impairment. In a transgenic mouse model of Alzheimer's disease, researchers reported that enkephalin elevations contributed to neuronal and behavioural impairments (PMID 18463254). This is the clearest statement in the set that more enkephalin can accompany worse outcomes.
• Pro-inflammatory cytokine output. Met-enkephalin was reported to augment interleukin-6 production by cytokine-stimulated murine macrophages (PMID 11021979). Amplified IL-6 is an inflammatory signal, not a neutral one, although the study was conducted in cultured cells.
• Association with liver disease states. Met-enkephalin immunoreactivity was characterised in human liver tissue from viral and autoimmune hepatitis (PMID 18753988), and plasma met-enkephalin, beta-endorphin and Leu-enkephalin were measured in patients with hepatic encephalopathy (PMID 17684846). Both papers situate enkephalin measurements inside serious disease, without establishing that the peptide caused the disease.
• Stress-related change in brain signal. Hippocampal mossy fibre Leu-enkephalin immunoreactivity was reported to be significantly altered after both acute and chronic stress in female rats (PMID 24275289), indicating that the system is sensitive to stressors.
• Reproductive exposure. Transplacental transfer of [Met⁵]-enkephalin was reported in rats (PMID 11489341), meaning the maternal–fetal barrier was not absolute for this peptide in that model.
• Addiction-relevant plasticity. Both reviews position enkephalin signalling within the neuroadaptations of psychostimulant addiction (PMID 29892236) and substance use disorders more broadly (PMID 35993087), a context in which changes in the system are discussed as pathological rather than beneficial.

Limits of the evidence in Module 4

Absence of reported adverse events here reflects absence of dosed human trials, not demonstrated safety. Cell-culture and rodent findings do not establish human risk profiles, and observational human studies cannot separate cause from consequence.

Module 5 — Pharmacokinetics Where Data Exist

Formal pharmacokinetic parameters — half-life, bioavailability, clearance, volume of distribution — were not published for enkephalin in any paper in this verified set. Three indirect observations are available.

Enzymatic breakdown

Enkephalin is a substrate for enkephalin-degrading enzymes, and the mouse study that combined Leu-enkephalin with spinorphin, an endogenous inhibitor of those enzymes, reported potentiated anti-allodynic and antinociceptive effects (PMID 11829145). The design implies that enzymatic degradation was a rate-limiting step on the peptide's duration of action in that model.

Route of administration

That same mouse work used intrathecal delivery (PMID 11829145), a route chosen in preclinical pain research to place peptide near spinal targets. No oral, subcutaneous or intravenous human pharmacokinetic study appears in this set.

Barrier crossing

Researchers reported transplacental transfer of [Met⁵]-enkephalin in rats (PMID 11489341), which is distribution information rather than a full kinetic profile. Separately, plasma concentrations of met-enkephalin, beta-endorphin and Leu-enkephalin were quantifiable in human blood samples in a hepatic encephalopathy study (PMID 17684846), confirming that endogenous circulating levels can be assayed.

Limits of the evidence in Module 5

No half-life, dose-proportionality or bioavailability value can be stated from this literature. Rodent placental transfer does not predict human transfer, and endogenous plasma levels in patients say nothing about the kinetics of administered peptide.

Module 6 — Regulatory Status, Stated Factually

Approved products

Enkephalin itself is not the active ingredient of an FDA-approved drug product in the United States. Approved opioid analgesics act at the same receptor family, but they are distinct small molecules and peptide analogues, not enkephalin. No paper in this verified set describes an approved enkephalin medicine.

Research-use-only status

Where enkephalin peptides are supplied to laboratories, they are typically distributed as research-use-only (RUO) chemicals. RUO material is not manufactured, tested or labelled as a drug for human administration, and the designation reflects an intended laboratory use rather than any safety determination. The studies summarised in this course are laboratory and clinical-observational research of exactly that kind — for example tissue immunohistochemistry in rats (PMID 24275289) and cell-culture work in murine macrophages (PMID 11021979).

Compounding

Under the US Federal Food, Drug, and Cosmetic Act, a bulk drug substance used in pharmacy compounding must generally be a component of an FDA-approved product, appear in an applicable USP or NF monograph, or be included on the relevant FDA bulk drug substances list. Peptides that meet none of those conditions fall outside the compounding pathways described in sections 503A and 503B. Separately, some peptide substances are treated as biological products, which changes the regulatory route again. Regulatory classifications change over time and differ by jurisdiction; this section is factual summary and is not legal advice.

Limits of the evidence in Module 6

Regulatory status is not a scientific endpoint and none of the cited papers addressed it. Status statements here describe categories and frameworks, not the quality, purity or safety of any specific material, and they do not imply that any use is appropriate.

What the Studies Did Not Test

Reading across all ten papers, the gaps are as important as the findings:

1. No dosed human trials. No study in this set administered enkephalin to human participants and measured efficacy or safety outcomes.
2. No long-term follow-up. The rodent and cell studies measured short-term endpoints; none reported multi-year outcomes.
3. No performance, body-composition or longevity endpoints. Those outcomes were not measured by any cited paper, so nothing about them can be inferred.
4. No dose-response mapping in humans. The mouse pain study varied pharmacological conditions rather than establishing a human dose-response relationship (PMID 11829145).
5. No causal link in the human observational work. Plasma and tissue measurements in liver disease reported associations only (PMID 17684846, PMID 18753988).
6. No therapeutic conclusion from the reviews. The addiction reviews described mechanisms and open questions rather than validated treatments (PMID 29892236, PMID 35993087).

Course takeaway: enkephalin is best understood from this literature as an endogenous opioid peptide system that researchers measure and manipulate in models to understand pain, stress, seizure biology, immune signalling, liver disease and addiction — not as a tested human therapy. Again, this page is educational only and is not medical advice.

References

• Enkephalin as a Pivotal Player in Neuroadaptations Related to Psychostimulant Addiction (Frontiers in Psychiatry, 2018)
• The role of enkephalinergic systems in substance use disorders (Frontiers in Systems Neuroscience, 2022)
• Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease (The Journal of Neuroscience, 2008)
• Proenkephalin Derived Peptides Are Involved in the Modulation of Mitochondrial Respiratory Control During Epileptogenesis (Frontiers in Molecular Neuroscience, 2018)
• Spinorphin, an endogenous inhibitor of enkephalin-degrading enzymes, potentiates leu-enkephalin-induced anti-allodynic and antinociceptive effects in mice (Japanese Journal of Pharmacology, 2001)
• Augmenting effect of methionine-enkephalin on interleukin-6 production by cytokine-stimulated murine macrophages (Neuropeptides, 2000)
• Hippocampal mossy fiber leu-enkephalin immunoreactivity in female rats is significantly altered following both acute and chronic stress (Journal of Chemical Neuroanatomy, 2014)
• Human hepatic met-enkephalin and delta opioid receptor-1 immunoreactivities in viral and autoimmune hepatitis (Annals of Hepatology, 2008)
• Plasma met-enkephalin, beta-endorphin and leu-enkephalin levels in human hepatic encephalopathy (Eastern Mediterranean Health Journal, 2007)
• Transplacental transfer of the opioid growth factor, [Met(5)]-enkephalin, in rats (Brain Research Bulletin, 2001)